+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free

Global Anxiety Disorders and Depression Treatment Market to Decline to US$18.2 bn by 2020 from US$22.5 bn in 2014

Posted on Nov 25, 2015

Transparency Market Research (TMR) has announced the release of the new report, titled “Anxiety Disorders and Depression Treatment Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020”. The global anxiety disorders and depression treatment market will decline at a moderate CAGR of 1.25% during the forecast period from 2014 to 2020. In 2013, the global anxiety disorders and depression treatment market was worth US$22.5 bn and by 2020, the market is expected to shrink to US$18.2 bn.

 

Browse the full Anxiety Disorders and Depression Treatment Market [Drug Classes: SSRIs, SNRIs, Benzodiazepines, Beta Blockers, TCAs, TeCAs, Atypical Antipsychotics, Anticonvulsants and MAOIs] - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020 report at http://www.transparencymarketresearch.com/anxiety-disorders-depression-treatments.html

The global anxiety disorders and depression treatment market is driven by the rising prevalence of depression and anxiety disorders. According to the WHO, presently, around 350 mn people are affected by depression. The global anxiety disorders and depression treatment market’s growth will also be encouraged by the reduced side effects and increased efficacy of drugs in various classes. Demand from the rising geriatric population will further fuel the global anxiety disorders and depression treatment market, as anxiety and depression are commonly observed in the geriatric population.

 

The global anxiety disorders and depression treatment market will demonstrate a moderate growth curve challenged by several market trends. The patent expiration of major drugs, growing number of generic drug variants, dry pipeline of novel drugs, and rising prevalence of drug-resistant mental disorders will challenge the growth of the global anxiety disorders and depression treatment market. Nevertheless, the improving distribution network in emerging economies will provide a good growth opportunity for players operating in the global anxiety disorders and depression treatment market.

 

On the basis of drug class, the global anxiety disorders and depression treatment market is segmented into atypical antipsychotics, monoamine oxidase inhibitors (MAOIs), beta blockers, anticonvulsants, tricyclic antidepressants (TCAs), serotonin-norepinephrine reuptake inhibitors (SNRIs), selective serotonin reuptake inhibitors (SSRIs), benzodiazepines, and tetracyclic antidepressants (TeCAs). In 2013, the global anxiety disorders and depression treatment market was led by SNRIs. The SNRIs segment held a share of ~30% in the global anxiety disorders and depression treatment market in 2013. Some of the top drugs in the pipeline in the global anxiety disorders and depression treatment market are ALKS-5461, brexpiprazole (OPC-34712), and Brintellix (vortioxetine - Lu AA21004).

 

Region-wise, the global anxiety disorders and depression treatment market is classified into Asia Pacific, Europe, North America, and Rest of the World (RoW). North America dominates the global anxiety disorders and depression treatment market due to the presence of a large patient population suffering from various anxiety disorders. The U.S. anxiety disorders and depression treatment market has reached saturation and many antidepressant drugs are available on prescription for the same symptom. Hence, players in the U.S. anxiety disorders and depression treatment market are focusing on introducing more effective drugs for new symptoms. Asia Pacific will experience moderate growth in the global anxiety disorders and depression treatment market due to demand from large emerging economies such as China and Japan.

 

A growing number of companies are focusing on providing herbal drugs to answer the rising demand from consumers for safer, natural drugs. Some of the key players operating in the global anxiety disorders and depression treatment market are Sanofi-Aventis, Pfizer, Johnson & Johnson, Eli Lilly and Company, and AstraZeneca.

 

Key Segments of the Global Anxiety Disorders and Depression Treatment Market

  • Anxiety Disorders and Depression Treatment Market, by Drug Class
    • Selective Serotonin Reuptake Inhibitors (SSRIs)
    • Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
    • Atypical Antipsychotics
    • Tricyclic Antidepressants (TCAs)
    • Tetracyclic Antidepressants (TeCAs)
    • Monoamine Oxidase inhibitors (MAOIs)
    • Benzodiazepines
    • Beta-Blockers
    • Anticonvulsants
  • Anxiety Disorders and Depression Treatment Market, by Geography
    • North America
    • Europe
    • Asia-Pacific
    • Rest of the World (RoW)

Browse : Our new press releases http://www.transparencymarketresearch.com/pressrelease/global-anxiety-disorders-depression-treatments.htm

About Us

 

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

 

TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

 

Contact

 

Mr.Sudip S
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

Back To Top